A pilot trial of bright light therapy in patients receiving first line immune checkpoint blockade

Clinical Trial Details

The purpose of this study is to evaluate the safety and effectiveness of bright light therapy for patients with melanoma and non-small cell lung cancer (NSCLC).

In this study, bright light therapy will be provided via an iPad at the participant's home for 60 minutes total.
   
Participation is expected to last 3 weeks.

Key Eligibility: 
  1. Open to men and women above the age of 18 who have been diagnosed with advanced, unresectable melanoma or NSCLC.
  2. Participants must not be pregnant or breastfeeding.

Detailed eligibility will be reviewed when contacting the study team.

Study contact by location

Upper East Side - Manhattan

Contact(s)

Daniella Topol, RN
212-746-4154
dat7032@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

2510029453

Sponsor:

IIT Circadian Rhythm

Status

Open to Enrollment

Age Group

Adult

Sponsor